J&J To Power Ahead With 10 Launches In Four Years
Set To Outpace Sector Again
Johnson & Johnson has achieved exceptional growth in recent years, and a raft of new products is set to sustain it further.
You may also be interested in...
Genentech will use the X-Chem platform to obtain leads against multiple oncology targets. Lilly partners with Merus on CD3-targeting T-cell therapy candidates.
Bristol makes its own deal with Celgene ally Dragonfly, while Gilead ends virology partnerships with Durect and Precision BioSciences.
A strong fourth quarter and full-year 2019 performance by J&J was driven by significant sales growth for Tremfya and Stelara. CFO Wolk said a $4bn opioids settlement remains on track.